Open an account

Accolade

ACCD · NASDAQ

Price unavailable right now.

No price history for this range.

About ACCD

Accolade, Inc. engages in the provision of technology-enabled health and benefits solutions. The company is headquartered in Plymouth Meeting, Pennsylvania. The firm provides personalized, technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits. Its customers are primarily employers that deploy Accolade solutions in order to provide employees and their families with a single place to turn for their health, healthcare, and benefits needs. The company also offers medical opinion services to commercial customers and virtual primary care and mental health support. Its platform, True Health Engine, combines open, cloud-based intelligent technology with multimodal support from a team of empathetic and knowledgeable Accolade Health Assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.

Employees
2,400
Headquarters
Plymouth Meeting, Pennsylvania
Listed
Jul 2, 2020
Sector
Health Care
Industry
Health Care Providers & Services
Website
accolade.com

ACCD key statistics

This section is temporarily unavailable. Refresh to try again.

ACCD earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 28.4% on average.

  1. Q4 FY23: reported -$0.42 per share against an estimate of -$0.4315
  2. Q1 FY24: reported -$0.52 per share against an estimate of -$0.6323
  3. Q2 FY24: reported -$0.43 per share against an estimate of -$0.5472
  4. Q3 FY24: reported -$0.28 per share against an estimate of -$0.451
  5. Q4 FY24: reported -$0.10 per share against an estimate of -$0.0722
  6. Q1 FY25: reported -$0.35 per share against an estimate of -$0.492
  7. Q2 FY25: reported -$0.30 per share against an estimate of -$0.4463
  8. Q3 FY25: reported -$0.31 per share against an estimate of -$0.725

ACCD news

  • Press releasePRNewswire

    Defining Wellness Centers Names Bill Morrison Chief Financial Officer

  • Press releaseBusiness Wire

    Transcarent Completes Merger With Accolade

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VOXX, ACCD, WMPN, AVAV on Behalf of Shareholders

  • Press releasePRNewswire

    STOCKHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of ACCD, SKGR, AVAV, WMPN to Act Now

  • Press releasePRNewswire

    Accolade Welcomes Oshi Health to Trusted Partner Ecosystem

  • Press releaseBusiness Wire

    ACCD Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Accolade, Inc. Is Fair to Shareholders

  • Press releasePRNewswire

    $HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger - YOTA, PORT, ACCD, ESSA

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ACCD, AVAV, VCSA, AMCR on Behalf of Shareholders

Similar companies

Companies in the same industry as Accolade

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.